OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacogenomics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Patient comprehension of preemptive pharmacogenomic results	47
Pharmacogenomic variants affecting efficacy and safety of medicines acting on central nervous system among Sri Lankans	28
How to implement pre-emptive pharmacogenetic testing in the acute hospital setting	27
Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis	26
Genetics and response to treatment with metformin for type 2 diabetes	21
Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization	19
Assessing patient understanding of pharmacogenomic test results: a qualitative study	16
Genetics of tardive dyskinesia: a review of progress over the past decade	15
Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review	13
Pharmacogenomics in Psychiatry – the Challenge of Cytochrome P450 Enzyme Phenoconversion and Solutions to Assist Precision Dosing	12
Acceptance of recommendations by a pharmacogenetics clinic	11
miR-369-3p regulates the drug resistance of lung cancer cells by targeting PTPN12	11
CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations	11
A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level	11
Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight	11
Characterization of CYP2C19 Pharmacogenetic Variation in African Populations and Comparison with Other Global Populations	11
Contrasting ABCB1 Pharmacogenetics and Psychotropic Responses in Child and Adolescent Psychiatry: A case comparison	10
Rapid point of care testing: the next frontier in pharmacogenomics	9
Gene Polymorphisms Affect Postoperative Imatinib Plasma Levels and Edema in Adults With Gastrointestinal Stromal Tumor	9
Integrated in a Systems Pharmacology Approach, Pharmacogenetics holds the Promise for Personalized Medicine in Neonates	9
Severe systemic Adverse Reactions to Ophthalmic Timolol in a CYP2D6 Homozygous *4 Allele Carrier: A Case Report	9
Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications	9
UGT1A1 Genotype-Guided Dosing of Irinotecan: Time to Prioritize Patient Safety	8
Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy	8
Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention	8

Improving the Management of ALK-Rearranged Non-Small-Cell Lung Cancer Through a Mobile Application: A Physicians-Based Survey	8
Prioritizing drugs for future clinical pharmacogenomics studies in Saudi Arabia: a generalizable multi-criteria framework	8
Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study	8
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics	8
Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models	8
A Survey of Physician Opinions in Russia in the Field of Pharmacogenetics of Cardiovascular Disease	8
Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration	8
The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma	7
SLCO1B1 and ABCB1 Variants Synergistically Influence the Atorvastatin Treatment Response in South Indian Coronary Artery Disease Patients	7
Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic H	7
Genetic polymorphisms and adverse reactions to antituberculosis therapy	7
EFfects of UGT1A , CYP2C9/19 and ABAT Polymorphisms on Plasma Concentration of Valproic Acid in Chinese Epi	7
Association of ACE I/D polymorphism with blood pressure response to valsartan-hydrochlorothiazide combination therapy in hypertensive patients from Khyber Pakhtunkhwa, Pakistan	7
Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study	7
Cost–Effectiveness of HLA-B58:01* Testing to Prevent Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in Vietnam	7
A critical review of RAF inhibitors in BRAF-mutated glioma treatment	7
DDX11-AS1 Modulates Dna Damage Repair to Enhance Paclitaxel Resistance of Lung Adenocarcinoma Cells	7
Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226	6
Knowledge and Attitudes of Incoming Pharmacy Students Toward Pharmacogenomics and Survey Reliability	6
Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data	6
Carbamazepine Cutaneous Adverse Reactions and HLA Gene Variation in the Chinese Population: A Systematic Review and Meta-Analysis	6
Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review	6
Donor-Derived Cell Free DNA as a Biomarker in Kidney Transplantation	6
TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience	6
Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients	6
Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion	6
Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations	6
Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain	5
Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial	5
XDH Genotypes Through Gene–Gene Interactions with NUDT15 Affect Azathioprine-Induced Leukopenia in Chinese Patients	5
Correction	5
The Revolution of Pharmaco-Omics: Ready to Open new Avenues in Materializing Precision Medicine?	5
Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case–control study	5
Predicting laboratory aspirin resistance in Chinese stroke patients using machine learning models by GP1BA polymorphism	5
DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?	5
Overview of the Year 2023 at Pharmacogenomics	5
Pharmacogenomics in Pediatric Medicine and Drug Development	5
Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases	5
Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: “It’s no different from your blood type”	5
Patient Satisfaction With Return of Pharmacogenomic Results Utilizing a Patient Portal Message	5
CYP2C:TG haplotype in Ecuador and Nicaragua: insights into CYP2C19 genotype–phenotype correlation in context to Mestizo popula	5
The Frequency Of Rs2231142 in ABCG2 Among Native Hawaiian nd Pacific Islander Subgroups: Implications for Personalized Rosuvastatin Dosing	5
The Importance of Phenoconversion when using the CYP2D6 Genotype in Clinical Practice	4
Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions	4
Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use	4
Association of CYP2C19 , CYP3A4 and ABCC2 Polymorphisms and Voriconazole Plasma Concentrations in Uygur Ped	4
Evaluation of Pentamidine Tolerability and Efficacy Between CYP2C19 Phenotypes	4
Artificial intelligence, medications, pharmacogenomics, and ethics	4
Impact of CYP2C19 Gene Polymorphisms on Warfarin Dose Requirement: A Systematic Review and Meta-Analysis	4
Relevance of NAT2 Genotype and Clinical Factors to Risk for Antituberculosis Drug-Induced Liver Injury	4

Single-Nucleotide Polymorphisms in ABC Drug Transporters Alter Expression and Circulating Tenofovir in Healthy South African Women Exposed to Pre-Exposure Prophylaxis	4
Genome-Wide Association Study of Liver Enzyme Elevation in an Extended Cohort of Rheumatoid Arthritis Patients Starting Low-Dose Methotrexate	4
Healthcare Professionals’ Knowledge, Confidence and Perceptions of Pharmacogenomics in Primary Care and Pain Management	4
Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review	4
Clinical Pharmacology and Pharmacogenomics for Implementation of Personalized Medicine	4
Leveraging Clinical Decision Support to Reduce the Risk of Discordant Pharmacogenomics Results	4
Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia	4
Influence of CYP3A5 , IL-10 Polymorphisms and Metabolism Rate on Tacrolimus Exposure in Renal Post-Transplant Recipients	4
Congruence Rates for Pharmacogenomic Noninterruptive Alerts	4
Liquid biopsy: an essential tool for metastatic breast cancer’s follow-up	4
Impact of ABCB1 gene polymorphism on clopidogrel plasma concentration and cardiovascular events in post-PCI patients	4
Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes	4
Variation in the ABC transporter genes and association with clinical outcomes in colorectal cancer: a brief review	4
Psychiatric Level 1A Evidence Pharmacogenomics in a Brazilian Admixed Cohort and Global Populations	4
Clinically actionable genetic variation in patients with or at high-risk of cardiovascular diseases from the Montreal Heart Institute	4
Pharmacogenomic curriculum in Australian medical schools: a content analysis study	4